生长抑素受体亚型与 EGFR在非小细胞肺癌中的表达及其临床意义

目的:探讨联合应用凋亡素(apoptin)基因、新城疫病毒(newcastle disease virus,NDV)血凝素-神经氨酸酶(he-magglutinin-neuramidinase,HN)基因及人白介素18(hIL-18)基因体外对人结肠癌细胞HCT-116的抑制效应。方法:重组质粒pIRApoptinHNIL18通过脂质体介导法体外转染人结肠癌细胞HCT-116,通过Western blotting和RT-PCR检测外源基因表达;采用AO/EB染色法检测pIRApoptinHNIL18对人结肠癌细胞HCT-116抑制作用;利用流式细胞术分析pIRApoptinHNIL18对人结肠癌细胞HCT-116线粒体膜电位(mitochondrial transmembrane potential,△Ψ)和活性氧(reactive oxygen species,ROS)水平;采用3,5-二羟基甲苯法测定唾液酸含量。结果:pIRApoptinHNIL18转染人结肠癌细胞HCT-116后,外源基因能够有效表达;肿瘤细胞生长受到抑制;线粒体△Ψ由(94.41±8.17)%下降到(30.70±8.01)%(P<0.05);唾液酸含量由(0.33±0.06)mmol/L下降到(0.09±0.03)mmol/L(P<0.01);ROS水平由(52.48±6.09)%升高到(68.98±7.26)%(P<0.05)。结论:pIRApoptinHNIL18可通过线粒体途径诱导细胞凋亡,从而抑制人结肠癌细胞HCT-116的生长。

Expression of somatostatin receptor subtypes and epidermal growth factor receptor in nonsmall cell lung cancer and their clinical significance

To investigate the expression of somatostatin receptors (SSTR) subtypes (SSTTR2A, and SSTR5) and epidermal growth factor receptor (EGFR) in nonsmall cell lung cancer (NSCLC) and their clinical relevance. Methods: The expressions of SSTR2A, SSTR5, and EGFR in 62 NSCLC specimens and 7 adjacent normal lung tissues were examined using immunohistochemical method (SP). All patients were followed up in this study. Results: The positive rates of SSTR2A and SSTR5 in the 62 specimens were 48.3% (30 cases) and 70.9% (44 cases), respectively. The positive rates of SSTR2A and SSTR5 were closely related to TNM stage (P<0.05), but not to patients' ages, sexes, smoking history, pathological types, tumor sizes, and lymph metastases (P>0.05). In the same group, EGFR expressed in 56.4% (35 cases) of NSCLC specimens, but was not expressed in the 7 normal spesimens. The positive rate of EGFR was not related to the ages, sexes, smoking history, histological types, tumor sizes, TNM stages, pathological classification, and lymph metastases (P>0.05). There was a negative correlation between the EGFR expression with the expression of SSTR2A and SSTR5 in NSCLC tissues. The 3year survival rates were 64.5% and 65.9% in patients positive of SSTR5 and SSTR2A, respectively; and were 45.2% and 22.2% for those negative of SSTR5 and SSTR2A, respectively (P<0.05). The 3year survival rate was 30.8% for patients positive of EGFR protein and 69.4% for those negative of it (P<0.05). Conclusion: The expressions of SSTR2A, SSTR5, and EGFR can reflect the biology behavior of lung cancer, and the examination of them may be helpful for evaluation of the lymph node metastases, pathological classification, and prognosis of NSCLC.